RMI Partners

RMI Partners is a venture capital firm established in 2012, primarily focused on fostering breakthrough developments in pharmaceutical products and technologies. Based in Moscow, Russia, with an interest in both Russian and U.S. markets, the firm positioned itself to capitalize on innovation within the life sciences sector. Its investment strategy typically targeted early-stage and growth-stage companies poised to disrupt the pharmaceutical and biotechnology landscapes.

The firm's investment mandate involved providing substantial capital to its portfolio companies. RMI Partners typically deployed first cheques ranging from $5 million to $20 million, indicating a preference for significant stakes in promising ventures. With reported assets under management (AUM) of $200 million, the firm had considerable resources dedicated to its specialized investment thesis. This substantial fund size allowed RMI Partners to support the often capital-intensive development cycles inherent in pharmaceutical and biotech innovation.

According to available data, RMI Partners made approximately 12 investments during its active period. However, a notable aspect of the firm's profile is the apparent cessation of new investment activity since late 2017. Their last publicly recorded investment was in October 2017, with a $15 million investment in Novira Therapeutics. The absence of more recent portfolio additions or public announcements suggests that RMI Partners may have become largely dormant or ceased new investment operations in the years following 2017. This lack of recent activity is a critical consideration for any prospective entrepreneur or co-investor.